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Abstract
Purpose Prediction of response to primary endocrine therapy (PET) in older women is based on measurement of oestrogen 
receptor (ER), progesterone receptor (PgR) and human epidermal growth factor (HER)-2. This study uses a unique method 
for construction of core needle biopsy (CNB) tissue microarray (TMA), to correlate expression of a panel of 17 biomarkers 
with clinical outcome, in patients receiving PET.
Methods Over 37 years (1973–2010), 1758 older (≥ 70 years) women with operable primary breast cancer were managed in 
a single institution. Of these, 693 had sufficient good-quality CNB to construct TMA, of which 334 had ER-positive tumours 
treated by PET with a minimum of 6-month follow-up. A panel of biomarkers was measured by immunohistochemistry (ER, 
PgR, HER2, Ki-67, p53, CK5/6, CK 7/8, EGFR, BCL-2, MUC1, VEGF, LKB1, BRCA1, HER3, HER4, PTEN and AIB1). 
Expression of each biomarker was dichotomised into ‘low’ or ‘high’ based on breast cancer-specific survival (BCSS).
Results From the panel of biomarkers, multivariate analysis showed:
– High ER (p = 0.003) and PgR (p = 0.002) were associated 
with clinical benefit of PET at 6 months, as opposed to 
progressive disease.
– High ER (p = 0.0023), PgR (p < 0.001) and BCL-2 
(p = 0.043) and low LKB1 (p = 0.022) were associated 
with longer time to progression.
– High PgR (p < 0.001) and low MUC1 (p = 0.021) were 
associated with better BCSS.
Expression of other biomarkers did not show any significant correlation.
Conclusions In addition to ER and PgR; MUC1, BCL-2 and LKB1 are important in determining the outcome of PET in 
this cohort.
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Introduction
Surgery has better locoregional control of primary breast 
cancer compared to primary endocrine therapy (PET) 
in older women [1]. The 2012 joint guidance from the 
International Society of Geriatric Oncology and Euro-
pean Society of Breast Cancer Specialists [2] recom-
mend that PET should only be offered to patients with 
oestrogen receptor (ER)-positive tumours with a life 
expectancy of 2–3 years despite optimisation of medi-
cal conditions. Despite this, around 40% of older women 
with primary breast cancer in the UK are treated by PET 
[3–5]. Determining who should have PET can be quite 
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subjective and dependent on interpretation of frailty and 
impact of comorbidity on quality of life. Patients report 
good satisfaction and low treatment morbidity with PET 
[2]. Furthermore, surgery and PET have been shown to 
have similar survival outcomes for up to 5 years [6]; thus, 
PET appears to be an attractive treatment option in some 
patients.
Overall, greater than 30% of patients with ER-positive 
primary breast cancer treated by surgery relapse despite 
endocrine therapy [7–9]. In addition to this, initiation of 
PET can take weeks to months before any clinical benefit 
is seen, and there is an unfortunate group of patients who 
exhibit no response following this.
Currently prediction of response to PET can only be 
based on the routinely measured receptors on breast can-
cer biopsy samples, i.e. ER, progesterone receptor (PgR) 
and human epidermal growth factor receptor 2 (HER2).
Expression of ER is heterogeneous and predictive 
value limited, as only 50–70% of patients with ER-posi-
tive tumours respond clinically to neoadjuvant endocrine 
therapy [10–12]. Progesterone expression is associ-
ated with good prognosis in ER-positive breast cancer, 
although its predictive role in endocrine therapy response 
remains unclear. In the adjuvant setting, PgR expression 
is associated with greater benefit from endocrine ther-
apy in some studies [13, 14], but not universally [15]. 
Whilst measurement of HER2 is used for prediction of 
anti-HER2-targeted therapy, it is also generally associ-
ated with a poor response to endocrine therapy [16, 17].
This variability indicates the need for other biomarkers 
that can predict those likely to respond to treatment and 
help to determine prognosis, specifically in the setting of 
primary therapy. Overall research in this area is limited. 
This is mainly due to the restriction of limited volume of 
tissue available for research from diagnostic core needle 
biopsy (CNB). On the other hand, with surgically treated 
patients, there is less of an issue regarding tumour tissue 
availability as surgical excision and conventional tissue 
microarray (TMA) technique can amplify tissue to meet 
the research requirements.
Following the development of a technique in our group 
to construct TMAs from diagnostic CNB, irrespective of 
primary treatment, we have successfully measured a large 
panel of biomarkers in these CNB TMAs [18].
The goal of this present study was to investigate, using 
CNB TMAs, the patterns of biomarker expression in 
patients treated by PET and their relationship to clinical 
outcome.
This was achieved through measurement of a panel of 
biomarkers and correlation with (i) clinical response to 
PET; (ii) time to progression (TTP) of disease and (iii) 
breast cancer-specific survival (BCSS).
Methods
Patient group
Over a 37-year period (1973–2010), 1758 older (≥ 70 years) 
women with early operable (< 5 cm, T0-2, N0-1, M0) pri-
mary breast cancer were managed in a dedicated clinic in 
Nottingham. Clinical information was available from diag-
nosis of breast cancer until death or last documented follow-
up and has been described previously [4, 19].
Selection of patients for the current study
It was possible to obtain diagnostic CNB blocks from 1221 
of the overall cohort. Of these, 693 cases had blocks with 
sufficient tumour tissue to construct CNB TMAs. From this 
group, 639 had tumours which were ER-positive. Positivity 
was defined as a histochemical (H) score ≥ 1 and measured 
positive on both diagnostic CNB and CNB TMA in 457 
cases, diagnostic CNB alone in 163 cases (measurement on 
CNB TMA inconclusive) and CNB TMA alone in 19 cases 
(diagnostic CNB result not available). Out of the ER-positive 
cases, 386 patients received PET and 334 had a minimum 
of 6-month follow-up data. Tamoxifen was the common-
est endocrine agent used (67.4%), followed by anastrozole 
(18.9%); the remaining patients had combined therapy. This 
information has been summarised in Supplementary File 1.
Construction of CNB TMA
Construction of TMAs from CNB was performed using a 
novel technique developed in our group [20, 21]. Briefly, 
based on tumour tissue availability, haematoxylin and eosin 
(H&E) slides and paraffin CNB blocks were reviewed and 
multiple areas of 4 mm of tumour were marked from each 
case, retrieved with skin biopsy punch. Taking into account 
the estimated average of continuous tumour cell (≥ 3 cm) 
available from diagnostic biopsy, the vertical re-arrangement 
method of transferring biopsy was chosen to be used and 
implanted in Agarose-paraffin TMA blocks. An Agarose-
paraffin block with a capacity of 54 core/block was used.
Measurement of panel of biomarkers
Immunohistochemical (IHC) staining of 17 biomarkers was 
performed using StreptAvidin Biotin Complex and EnVi-
sion methods (DakoCytomation) [22]. The biomarkers 
measured were ER, PgR, Ki-67, epidermal growth factor 
receptor (EGFR), HER2, HER3, HER4, p53, cytokeratins 
CK5/6 and CK7/8, Mucin (MUC)1, liver kinase B1 (LKB1), 
breast cancer-associated gene (BRCA) 1, B-cell lymphoma 
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(BCL)-2, phosphate and tensin homologue (PTEN), vascular 
endothelial growth factor (VEGF) and amplified in breast 
cancer 1 (AIB1).
The expression of biomarkers was assessed using the 
H-score scoring system (range 0–300) [23] with the excep-
tion of HER2, which was scored using the Herceptest scor-
ing system [24] and involves scoring the staining of the 
membrane (0–3). A TMA core with < 15% tumour material 
was deemed inadequate and not scored.
Given that we used a historical CNB samples and a novel 
technique to construct TMA from CNB (with a different 
diameter in terms of section face comparing to standard 
technique), we hypothesised that these two factors may affect 
the antigenicity of targeted markers. Therefore, to estimate 
the prognostic value of the biomarkers, expression of each 
biomarker was dichotomised using X-tile software (Version 
3.6.1, 2003–2005, University of Yale, Yale, USA [25]) into 
‘low expression’ and ‘high expression’, based on observed 
differences in survival over time.
Correlation of biomarker expression with clinical 
response to PET
Assessment of response to PET was done using the Union 
for International Cancer Control (UICC) criteria [26]. Clini-
cal benefit (CB) was defined as complete or partial response, 
or stable disease at 6 months. Biomarker expression (either 
‘high’ or ‘low’) was correlated with CB.
Correlation of biomarker expression with time 
to progression (TTP)
Biomarker expression (either ‘high’ or ‘low’) was corre-
lated with TTP, which was defined as time from diagnosis 
to progressive disease (progression of primary tumour or 
metastatic spread, as defined by UICC criteria).
Correlation with BCSS
Biomarker expression (either ‘high’ or ‘low’) was correlated 
with BCSS, which was calculated from date of diagnosis to 
death from breast cancer.
Statistical analysis
The statistical package SPSS was used for data collection 
and analysis. Cox-regression model was used to quantify 
the effect of a biological variable on a clinical variable. A 
2-tailed p-value of less than 0.05 was determined to be sta-
tistically significant.
Results were reported as per Reporting Recommenda-




The characteristics of the cohort are described in Table 1. 
The median age of patients was 81 years (range 70–99). 
Most patients had a grade 2 tumour measuring ≤ 3 cm, 
with moderate expression of ER. Multivariate analysis of 
standard histological variables is presented in Supplemen-
tary File 2.
Measurement of panel of biomarkers
Within a TMA specimen, not all the samples were equally 
robust to allow IHC staining for each individual sample. 
Table 2 details the total number of samples possible to 
test for each biomarker as well as the H-score cut-off to 
differentiate between high and low expression.
At 6  months after starting PET, 97.3% of patients 
showed evidence of clinical benefit (Table 3).
Table 1  Patient and tumour characteristics of older women with pri-
mary breast cancer treated with primary endocrine therapy
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From the extensive list of biomarkers (Table 4), logistic 
regression indicated that high expressions of ER (p = 0.003) 
and PgR (p = 0.002), compared to low expression, were sig-
nificantly associated with benefit from PET at 6 months.
Correlation of biomarker expression with TTP
From the cohort of 334 patients, 46% (n = 143) showed pro-
gressive disease at last follow-up, with a median TTP of 
50 months (range of 3–132 months).
From the panel of biomarkers tested, multivariate analysis 
showed that high expression of ER (p = 0.023) (Fig. 1a), PgR 
(p < 0.0010) (Fig. 1b), BCL-2 (p = 0.043) (Fig. 1c) and low 
expression of LKB1 (p = 0.022) (Fig. 1d) were significant 
predictors for longer TTP in this cohort.
Correlation of biomarker expression with BCSS
From the panel of biomarkers tested, multivariate analysis 
showed that high expression of PgR (p < 0.001) (Fig. 2a) and 
low expression of MUC1 (p = 0.021) (Fig. 2b) were signifi-
cant predictors of increased BCSS in this cohort.
Discussion
Correlation of biomarker expression with clinical 
response to PET
High ER and PgR expressions were associated with com-
plete or partial response to PET at 6 months. These find-
ings add to the growing body of evidence to support PgR as 
an independent predictive marker of response to endocrine 
therapy [13, 14, 28]. Tumours that are ER positive are often 
also PgR positive; thus, the significance of PgR on its own 
is sometimes overlooked. Expression of PgR serves as an 
indicator of a functionally intact nuclear ER pathway, so 
may help to predict which patients will respond to hormone 
therapies [29]. PgR expression has been associated with 
greater benefit from endocrine therapy in the adjuvant set-
ting [13, 30].
The present study has clinical implications for the use of 
PgR as a marker of response to neoadjuvant endocrine ther-
apy. When using endocrine therapy as primary treatment, 
any CB is important as a marker of survival. When using 
endocrine therapy in the neoadjuvant setting, achieving a 
complete or partial response is paramount when downsizing 
the tumour is the desired outcome.
In our previous study of 536 ER-positive patients within 
the overall cohort of older women [18], following examina-
tion of a panel of biomarkers, cluster analysis was performed 
and revealed three distinct biological clusters in these cases. 
Two of the clusters were consistent with well-known sub-
types (luminal A like and luminal B like). The third cluster, 
named ‘low ER luminal’ had higher expression of CK 7/8, 
BRCA, 2 and BCL-2, and lower expression of ER compared 
to the conventional clusters.
Patients in the luminal A-like cluster had similar sur-
vival outcomes whether they were treated by surgery or 
PET. Patients in luminal B like had better survival if they 
had surgery as opposed to PET. Although overall the low 
ER luminal cluster had lower BCSS compared to both the 
conventional clusters, within the cluster, patients responded 
equally well to either surgery or PET. This could be inter-
preted as both surgery and PET being equally as effective 
to treat this group of patients and suggests that in addition 
to conventional features, expression of CK7/8, BRCA2 and 
BCL-2 may be significant in the role of response to PET.
Table 2  H-score cut-off between high and low expressions of each 
biomarker
*Given as H-score for all biomarkers with exception to HER2, for 
which Herceptest is used
Biomarker Total number of sam-
ples able to test (N)



















Table 3  Summary of response to primary endocrine therapy at 6 
months based on international union against cancer criteria
Clinical outcome Number of 
patients (percent-
age)
Responses to primary endocrine therapy at 6 months (N = 334)
Complete response (CR) 39 (11.7)
Partial response (PR) 124 (37)
Stable disease (SD) 162 (48.5)
Progressive disease (PD) 9 (2.7)
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Correlation of biomarker expression with TTP
High ER, PgR and BCL-2 and low expression of LKB1 
were associated with longer TTP. This is clinically rel-
evant for older frail women who may have competing 
causes of death; knowing the length of time a cancer can 
be controlled by PET may impact their treatment decision 
making.
The protein BCL-2 is involved in the regulation of cell 
death through interference with the apoptosis pathway and 
is a ‘pro-survival’ protein in many types of cancer [31]. 
Biological characterisation of over 14,000 primary breast 
cancers has shown an increase in BCL-2 expression with 
age [13]. This present study adds to the evidence that breast 
cancer in older women has a less aggressive phenotype com-
pared to younger women.
LKB1 is a tumour suppressor gene, of which there is 
little research in the setting of older women. Studies have 
shown that LKB1 can inhibit the aromatase enzyme with the 
AMP-activated protein kinase, supporting its potential role 
in prediction of response to primary endocrine therapy [32, 
33]. In a recent analysis of all patients undergoing surgery 
within the current cohort of older women described in this 
present study, older women had higher expression of LKB1 
compared to a younger cohort [32]. LKB1 expression was 
associated with better survival among patients receiving 
adjuvant endocrine therapy, but TTP was not reported. These 
results appear contrary to the findings in this present study; 
low LKB1 expression has been associated with increased 
TTP of disease.
The authors hypothesise that the contradictory results 
in these two studies may be related to the context of the 
Table 4  Summary of 
association between biomarker 
expression and response to PET 
at 6 months
Biomarker Expression status Response at 6 months
N (%)
p-value
Progressive disease (PD) 
(N = 9, 2.69%)
Clinical benefit (CB) 
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studies. In the paper by Syed et al. [32], LKB1 was measured 
in surgical samples; in the present study, LKB1 has been 
measured on CNB samples in patients treated by PET. There 
could be fundamental differences between these two groups 
of patients due to treatment selection; however, further work 
is required to confirm this.
Fig. 1  Time to disease progression, older women with primary breast 
cancer treated with primary endocrine therapy (results of univariate 
analysis) – stratified based on a ER expression, b PgR expression, c 
LKB1 expression, d BCL-2 expression (p values reported are based 
on univariate analysis)
Fig. 2  Breast-cancer-specific survival of older women with primary breast cancer treated with primary endocrine therapy (results of univariate 
analysis) – stratified based on a PgR degree of expression and b MUC1 degree of expression (p values reported are based on univariate analysis)
Breast Cancer Research and Treatment 
1 3
Correlation of biomarker expression with BCSS
High expression of PgR and low expression of MUC1 were 
associated with better BCSS in this cohort. Correlation with 
BCSS reflects the biological behaviour of breast cancer in 
this cohort. Overall survival (OS) in older women is heavily 
influenced by competing causes of death. Therefore, under-
standing the biological features which contribute to BCSS 
and in-depth assessment of frailty, will lead to improved 
understanding of OS in this cohort.
These findings are consistent with work previously con-
ducted in 536 ER-positive cases of the overall cohort (irre-
spective of treatment type) [18]. This suggests that outcome 
is related to the inherent biology of the tumour, regardless 
of treatment.
Mucin-1 is an epithelial cell surface protein that is over-
expressed in up to 90% of breast cancers [34]. MUC1 over-
expression has been associated with shorter BCSS in inva-
sive breast cancer but in cases primarily receiving surgical 
treatment [35, 36] and not specific to older women.
Summary
In summary, the present study has shown that high expres-
sion of ER, PgR and BCL-2 and low expression MUC1 and 
LKB1 are associated with better outcome in older women 
treated with PET.
Strengths of the study
Although the markers found to be significant in this current 
study have been studied to varying degrees in the literature 
concerning breast cancer, most research is usually not spe-
cific to older women and usually performed in the adjuvant 
setting. Therefore, this present study is unique in testing a 
large panel of biomarkers prior to any oncological treatment.
Understanding which biological markers improve BCSS 
in this cohort in combination with assessment of frailty, 
may improve OS. This will have impact for consideration 
of endocrine therapy as neoadjuvant, primary and adjuvant 
treatment.
Weaknesses of the study
Due to the small volume of tissue available to construct 
CNB TMA, it was not possible to construct CNB TMA in 
all samples and some of the samples degraded on analysis. 
No direct comparison has been made between SE TMA and 
CNB TMA to check for concordance.
This study is based in a historic series of patients who 
were diagnosed with breast cancer as far back as 1973. The 
main endocrine agent used at the time was tamoxifen, which 
is not as effective as aromatase inhibitors, which are now 
routinely used in post-menopausal women. Therefore, sur-
vival of this cohort may be not as good overall as expected 
from a present-day population.
Future directions
The described technique of CNB TMA construction needs 
to be validated by other centres. Bioinformatics principles 
and technologies [37] could help to analyse a large database 
comparing biomarker expression with clinical outcome, into 
a format which could be used clinically (e.g. at diagnosis) 
to help inform patients when making the decision between 
primary surgery and PET.
Conclusions
This present study is unique in the examination of a large 
panel of biomarkers and their application to primary treat-
ment of operable breast cancer in older women. The study 
adds to the evidence base that breast cancer in older women 
is generally less aggressive than in their younger counter-
parts. Alongside the routinely measured markers ER and 
PgR, BCL-2, MUC1 and LKB1 may be important in deter-
mining response to PET and warrant further research.
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